Cloridarol

Cloridarol (25-125 µM; 0-20 h) inhibits hIAPP aggregation in a dose-dependent manner, reducing final fibril formation by up to 55.6%^[1].
Cloridarol (125 µM; 5-24 h) modifies hIAPP aggregate morphology and inhibits its secondary structure transition to β-sheet, maintaining random coil structure^[1].
Cloridarol (125 µM; 0-25 h) inhibits hIAPP aggregation from lag and early growth phase seeds but not from equilibrium phase fibrils^[1].
Cloridarol (25-125 µM; 24-48 h) protects RIN-m5F cells from hIAPP-induced toxicity, as evidenced by an increase in cell viability and a decrease in apoptosis^[1].
Cloridarol (50 µM; 0-900 min) reduces hIAPP-induced membrane leakage in large unilamellar vesicle (LUV)s, contributing to its protective effect against hIAPP toxicity^[1].
Cloridarol binds to the C-terminal β-sheet region of the hIAPP pentamer, disturbing its structure and reducing β-sheet content to inhibit aggregation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.